Neuroactive Steroids. 2. 3α-Hydroxy-3β-methyl-21-(4-cyano-1 H -pyrazol-1′-yl)-19-nor-5β-pregnan-20-one (SAGE-217): A Clinical Next Generation Neuroactive Steroid Positive Allosteric Modulator of the (γ-Aminobutyric Acid) A Receptor
The DOI matches its Crossref record; 25 of the 26 references it cites were found in a registry or an index.
Abstract
Certain classes of neuroactive steroids (NASs) are positive allosteric modulators (PAM) of synaptic and extrasynaptic GABA A receptors. Herein, we report new SAR insights in a series of 5β-nor-19-pregnan-20-one analogues bearing substituted pyrazoles and triazoles at C-21, culminating in the discovery of 3α-hydroxy-3β-methyl-21-(4-cyano-1 H -pyrazol-1′-yl)-19-nor-5β-pregnan-20-one (SAGE-217, 3 ), a potent GABA A receptor modulator at both synaptic and extrasynaptic receptor subtypes, with excellent oral DMPK properties. Compound 3 has completed a phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) clinical trial and is currently being studied in parallel phase 2 clinical trials for the treatment of postpartum depression (PPD), major depressive disorder (MDD), and essential tremor (ET).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“NAS GABAAR PAMs have pharmacological profiles and binding sites distinct from benzodiazepines,40,41 with the ability to modulate the activity of both synaptic and extrasynaptic GABAARs.39,42”
From Effect of Zuranolone vs Placebo in Postpartum Depression (2021) · cites this paper as [42]
Citations
Cites
Steroid hormone metabolites are barbiturate-like modulators of the GABA receptor
Majewska, M. D., Harrison, N. L., Schwartz, R. D., Barker, J. L., & Paul, S. M. (1986) · Science · doi:10.1126/science.2422758 · Cited by 2,225
The GABAergic deficit hypothesis of major depressive disorder
Luscher, B., Shen, Q., & Sahir, N. (2011) · Molecular Psychiatry · doi:10.1038/mp.2010.120 · Cited by 934
Endogenous neurosteroids regulate GABAA receptors through two discrete transmembrane sites
Hosie, A. M., Wilkins, M. E., da Silva, H. M. A., & Smart, T. G. (2006) · Nature · doi:10.1038/nature05324 · Cited by 752
Neurosteroids and GABAA receptor function
Lambert, J. J., Belelli, D., Hill-Venning, C., & Peters, J. A. (1995) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(00)89058-6 · Cited by 746
GABAergic dysfunction in mood disorders
Brambilla, P., Perez, J., Barale, F., Schettini, G., & Soares, J. C. (2003) · Molecular Psychiatry · doi:10.1038/sj.mp.4001362 · Cited by 553
GABA-based therapeutic approaches: GABAA receptor subtype functions
RUDOLPH, U., & MOHLER, H. (2006) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2005.10.003 · Cited by 499
Extrasynaptic GABA A Receptors: Form, Pharmacology, and Function
Belelli, D., Harrison, N. L., Maguire, J., Macdonald, R. L., Walker, M. C., & Cope, D. W. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.3340-09.2009 · Cited by 464
A single histidine in GABAA receptors is essential for benzodiazepine agonist binding.
Wieland, H. A., Lüddens, H., & Seeburg, P. H. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)45961-3 · Cited by 447
Impact of solid state properties on developability assessment of drug candidates
Huang, L. (2004) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2003.10.007 · Cited by 438
Subunit-Specific Trafficking of GABAAReceptors during Status Epilepticus
Goodkin, H. P., Joshi, S., Mtchedlishvili, Z., Brar, J., & Kapur, J. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.3426-07.2008 · Cited by 322
Research works printed but not linked: 1
- 10.1016/j.eplepsyres.2015.01.001 · DOI · Paper page
Cited by
Neurosteroids as novel antidepressants and anxiolytics: GABA-A receptors and beyond
Zorumski, C. F., Paul, S. M., Covey, D. F., & Mennerick, S. (2019) · Neurobiology of Stress · doi:10.1016/j.ynstr.2019.100196 · Cited by 305
Effect of Zuranolone vs Placebo in Postpartum Depression
Deligiannidis, K. M., Meltzer-Brody, S., Gunduz-Bruce, H., Doherty, J., Jonas, J., Li, S., Sankoh, A. J., Silber, C., Campbell, A. D., Werneburg, B., et al. (2021) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2021.1559 · Cited by 277
Self-citationBipolar depression: a major unsolved challenge
Baldessarini, R. J., Vázquez, G. H., & Tondo, L. (2020) · International Journal of Bipolar Disorders · doi:10.1186/s40345-019-0160-1 · Cited by 235
Trial of SAGE-217 in Patients with Major Depressive Disorder
Gunduz-Bruce, H., Silber, C., Kaul, I., Rothschild, A. J., Riesenberg, R., Sankoh, A. J., Li, H., Lasser, R., Zorumski, C. F., Rubinow, D. R., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1815981 · Cited by 232
Self-citationWhere Do Recent Small Molecule Clinical Development Candidates Come From?
Brown, D. G., & Boström, J. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00675 · Cited by 176
Cutler, A. J., Mattingly, G. W., & Maletic, V. (2023) · Translational Psychiatry · doi:10.1038/s41398-023-02514-2 · Cited by 192
Structural and functional biology of aldo-keto reductase steroid transforming enzymes
Penning, T. M., Wangtrakuldee, P., & Auchus, R. J. (2019) · Endocrine Reviews · doi:10.1210/er.2018-00089 · Cited by 164
Pharmacotherapy of Postpartum Depression: Current Approaches and Novel Drug Development
Frieder, A., Fersh, M., Hainline, R., & Deligiannidis, K. M. (2019) · CNS Drugs · doi:10.1007/s40263-019-00605-7 · Cited by 156
Althaus, A. L., Ackley, M. A., Belfort, G. M., Gee, S. M., Dai, J., Nguyen, D. P., Kazdoba, T. M., Modgil, A., Davies, P. A., Moss, S. J., et al. (2020) · Neuropharmacology · doi:10.1016/j.neuropharm.2020.108333 · Cited by 135
“A.L. Althaus et al. Neuropharmacology 181 (2020) 108333 were previously reported and determined to support daily oral dosing (Martinez-Botella et al., 2017).”
BackgroundMethodResultInfluentialSelf-citationLuo, W., Liu, Y., Qin, H., Zhao, Z., Wang, S., He, W., Tang, S., & Peng, J. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116838 · Cited by 113
Lüscher, B., & Möhler, H. (2019) · F1000Research · doi:10.12688/f1000research.18758.1 · Cited by 105
Cerne, R., LIPPA, A. S., Poe, M. M., Smith, J. L., Jin, X., Ping, X., Golani, L. K., Cook, J. M., & Witkin, J. M. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.108035 · Cited by 94
Clayton, A. H., Lasser, R., Parikh, S. V., Iosifescu, D. V., Jung, J., Kotecha, M., Forrestal, F., Jonas, J., Kanes, S. J., & Doherty, J. (2023) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20220459 · Cited by 87
Self-citationImpact of Allosteric Modulation in Drug Discovery: Innovation in Emerging Chemical Modalities
Han, B., Salituro, F. G., & Blanco, M.-J. (2020) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.9b00655 · Cited by 75
Self-citationAllopregnanolone in mood disorders: Mechanism and therapeutic development
Chen, S., Gao, L., Li, X., & Ye, Y. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105682 · Cited by 75
New drug approvals for 2019: Synthesis and clinical applications
Yuan, S., Yu, B., & Liu, H. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112667 · Cited by 72
Realising the therapeutic potential of neuroactive steroid modulators of the GABAA receptor
Belelli, D., Hogenkamp, D., Gee, K. W., & Lambert, J. J. (2020) · Neurobiology of Stress · doi:10.1016/j.ynstr.2019.100207 · Cited by 67
Hoffmann, E., Nomikos, G. G., Kaul, I., Raines, S., Wald, J., Bullock, A., Sankoh, A. J., Doherty, J., Kanes, S. J., & Colquhoun, H. (2020) · Clinical Pharmacokinetics · doi:10.1007/s40262-019-00801-0 · Cited by 59
“SAGE-217 potentiates representative examples of both synaptic and extrasynaptic GABAA receptors, preclinically differentiating it from other, currently approved GABAA receptor PAMs, such as members of the benzodiazepine class [1].”
BackgroundInfluentialSelf-citationEffect of Zuranolone on Concurrent Anxiety and Insomnia Symptoms in Women With Postpartum Depression
Deligiannidis, K. M., Citrome, L., Huang, M., Acaster, S., Fridman, M., Bonthapally, V., Lasser, R. A., & Kanes, S. (2023) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.22m14475 · Cited by 64
GABA System in Depression: Impact on Pathophysiology and Psychopharmacology
Vecchia, A. D., Arone, A., Piccinni, A., Mucci, F., & Marazziti, D. (2021) · Current Medicinal Chemistry · doi:10.2174/0929867328666211115124149 · Cited by 60
Synthetic Approaches to the New Drugs Approved during 2019
Flick, A. C., Leverett, C. A., Ding, H. X., McInturff, E. L., Fink, S. J., Mahapatra, S., Carney, D. W., Lindsey, E. A., DeForest, J. C., France, S. P., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00208 · Cited by 60
Review of Allopregnanolone Agonist Therapy for the Treatment of Depressive Disorders
Walkerly, A., Leader, L. D., Cooke, E., & VandenBerg, A. (2021) · Drug Design Development and Therapy · doi:10.2147/dddt.s240856 · Cited by 56
Kinjo, M., Wada, M., Nakajima, S., Tsugawa, S., Nakahara, T., Blumberger, D. M., Mimura, M., & Noda, Y. (2020) · Psychological Medicine · doi:10.1017/s0033291720004729 · Cited by 52
“Another promising pharmacological treatment for MDD is a novel GABAA receptor positive allosteric modulator known as SAGE-217 (3α-hydroxy-3β-methyl-21-(4-cyano-1H-pyrazol-1′yl)-19-nor-5β-pregnan-20-one) (Martinez Botella et al., 2017).”
BackgroundSynthesis and clinical application of new drugs approved by FDA in 2023
Wang, Y., Yang, P., Zhang, Y., & Sun, J. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116124 · Cited by 52
Witkin, J. M., LIPPA, A. S., Smith, J. L., Jin, X., Ping, X., Biggerstaff, A., Kivell, B. M., Knutson, D. E., Sharmin, D., Pandey, K. P., et al. (2022) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2021.173321 · Cited by 51
Essential tremor: Clinical perspectives and pathophysiology
Pan, M., & Kuo, S. (2022) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2022.120198 · Cited by 56
Breakthroughs in neuroactive steroid drug discovery
Blanco, M.-J., La, D. S., Coughlin, Q., Newman, C. A., Griffin, A. M., Harrison, B. L., & Salituro, F. G. (2017) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2017.11.043 · Cited by 47
Self-citationRichardson, E., Patterson, R., Meltzer-Brody, S. E., McClure, R. W., & Tow, A. C. (2024) · Annual Review of Medicine · doi:10.1146/annurev-med-050423-095712 · Cited by 52
Time-sensitive changes in the maternal brain and their influence on mother-child attachment
Nehls, S., Losse, E. M., Enzensberger, C., Frodl, T., & Chechko, N. (2024) · Translational Psychiatry · doi:10.1038/s41398-024-02805-2 · Cited by 48
Synthesis and antitumor activity of novel steroidal imidazolium salt derivatives
Deng, G., Zhou, B., Wang, J., Chen, Z., Gong, L., Gong, Y., Wu, D., Li, Y., Zhang, H., & Yang, X. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.02.025 · Cited by 44
Clinical specificity profile for novel rapid acting antidepressant drugs
Scala, M., Fanelli, G., De Ronchi, D., Serretti, A., & Fabbri, C. (2023) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000488 · Cited by 41
Current and Future Neuropharmacological Options for the Treatment of Essential Tremor
Alonso‐Navarro, H., García‐Martín, E., Agúndez, J. A. G., & Jiménez‐Jiménez, F. J. (2020) · Current Neuropharmacology · doi:10.2174/1570159x18666200124145743 · Cited by 39
Balan, I. S., Boero, G., Chéry, S. L., McFarland, M. H., Lopez, A. G., & Morrow, A. L. (2024) · Life · doi:10.3390/life14050582 · Cited by 44
Kaufman, Y., Carlini, S. V., & Deligiannidis, K. M. (2022) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253211065859 · Cited by 41
Wald, J., Henningsson, A., Hanze, E., Hoffmann, E. C., Li, H., Colquhoun, H., & Deligiannidis, K. M. (2022) · Clinical Pharmacokinetics · doi:10.1007/s40262-022-01155-w · Cited by 35
Self-citationGreenwald, M. K. (2018) · Neurobiology of Stress · doi:10.1016/j.ynstr.2018.08.003 · Cited by 34
Parikh, S. V., Aaronson, S. T., Mathew, S. J., Alva, G., DeBattista, C., Kanes, S., Lasser, R. A., Bullock, A. E., Kotecha, M., Jung, J., et al. (2023) · Neuropsychopharmacology · doi:10.1038/s41386-023-01751-9 · Cited by 36
“…of synaptic and extrasynaptic GABA A Rs and the second NAS approved by the FDA as an oral, once-daily, 14-day treatment course in adults with PPD [26, 27] and under investigation (as a monotherapy or adjunct therapy) for adults with MDD in the LANDSCAPE clinical development program [27 – 31].”
Self-citationZuranolone as an oral adjunct to treatment of Parkinsonian tremor: A phase 2, open-label study
Bullock, A. E., Kaul, I., Li, S., Silber, C., Doherty, J., & Kanes, S. (2020) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2020.117277 · Cited by 31
Self-citationNeurosteroid enantiomers as potentially novel neurotherapeutics
Covey, D. F., Evers, A. S., Izumi, Y., Maguire, J. L., Mennerick, S. J., & Zorumski, C. F. (2023) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2023.105191 · Cited by 31
“…strongly suggest that certain enantiomeric androstanes could be developed for therapeutic purposes based on GABAergic activity, including possible antidepressant, anxiolytic, anesthetic, anticonvulsant, analgesic, neurogenic and neuroprotective effects (Melcangi et al., 2021; Kelava et al., 2022).”
Kato, M., Nakagome, K., Baba, T., Sonoyama, T., Okutsu, D., Yamanaka, H., Shimizu, R., Motomiya, T., & Inoue, T. (2023) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.13569 · Cited by 32
“(similar to allopregnanolone), is in clinical development as an oral, once-daily, 14-day treatment course for adults with MDD and postpartum depression.(18) Several preclinical studies have suggested that allopregnanolone may exert an antidepressant effect by reducing the physiological effects of stress, promoting neu…”
BackgroundSharma, R., Bansal, P., Saini, L. K., Sharma, N., & Dhingra, R. (2024) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2024.173734 · Cited by 33
Vasiliu, O. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.884143 · Cited by 34
Keeping up with the clinical advances: depression
Ragguett, R.-M., Tamura, J. K., & McIntyre, R. S. (2019) · CNS Spectrums · doi:10.1017/s1092852919001159 · Cited by 27
Kudová, E. (2021) · Neuroscience Letters · doi:10.1016/j.neulet.2021.135771 · Cited by 25
Suthoff, E. D., Kosinski, M. R., Arnaud, A. M., Hodgkins, P., Gunduz‐Bruce, H., Lasser, R. A., Silber, C., Sankoh, A. J., Li, H., WERNEBURG, B. G., et al. (2022) · Journal of Affective Disorders · doi:10.1016/j.jad.2022.03.068 · Cited by 25
Self-citationCarlini, S. V., Osborne, L. M., & Deligiannidis, K. M. (2023) · Dialogues in Clinical Neuroscience · doi:10.1080/19585969.2023.2262464 · Cited by 27
Lin, Y., Tu, Y., Hung, K., Liang, C., Tseng, P., Lin, P., Lai, E. C., & Hsu, C. (2023) · EClinicalMedicine · doi:10.1016/j.eclinm.2023.102308 · Cited by 24
Li, Z., Wu, Q., Peng, P., Wu, M., Liu, S., & Liu, T. (2023) · Psychiatry Research · doi:10.1016/j.psychres.2023.115640 · Cited by 26
A comprehensive review of small molecule drugs approved by the FDA in 2023: Advances and prospects
Bai, Y., Seng, D., Xu, Y. C., Zhang, Y., Zhou, W., Jia, Y.-Y., Song, J. Z., He, Z., Liu, H., & Yuan, S. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116706 · Cited by 25
Clinical efficacy and safety of Zuranolone (SAGE-217) in individuals with major depressive disorder
Meshkat, S., Teopiz, K. M., Vincenzo, J. D. D., Bailey, J., Rosenblat, J. D., Ho, R., Rhee, T. G., Ceban, F., Kwan, A. T. H., Cao, B., et al. (2023) · Journal of Affective Disorders · doi:10.1016/j.jad.2023.08.027 · Cited by 23
Cytotoxic polyhydroxylated steroids from the South China Sea soft coral Lobophytum sp.
Zhāng, Q., Liang, L., Miao, Z., Wu, B., & Guo, Y. (2018) · Steroids · doi:10.1016/j.steroids.2018.11.015 · Cited by 23
Brexanolone for the treatment of patients with postpartum depression
Morrison, K. E., Cole, A. B., Thompson, S. M., & Bale, T. L. (2019) · Drugs of today · doi:10.1358/dot.2019.55.9.3040864 · Cited by 24
“Sage also states that SAGE-217 has low intrinsic clearance with potential for once-daily dosing (63).”
BackgroundAllosteric Modalities for Membrane-Bound Receptors: Insights from Drug Hunting for Brain Diseases
Coughlin, Q., Hopper, A. T., Blanco, M.-J., Tirunagaru, V. G., Robichaud, A. J., & Doller, D. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01651 · Cited by 23
Self-citationNew Pharmacologic Approaches to the Treatment of Bipolar Depression
Keramatian, K., Chakrabarty, T., DuBow, A., Saraf, G., & Yatham, L. N. (2023) · Drugs · doi:10.1007/s40265-023-01872-x · Cited by 22
“Allopregnanolone is also a GABAA receptor modulator with preferential activity at receptors with a δ-subunit that also binds to extrasynaptic sites [67, 68].”
BackgroundSynthetic Approaches to the New Drugs Approved during 2023
France, S. P., Lindsey, E. A., McInturff, E. L., Berritt, S., DeForest, J. C., Flick, A. C., Fink, S. J., Gibson, T., Gray, K. C., Hubbell, A. K., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c02079 · Cited by 20
In Search of GABAA Receptor’s Neurosteroid Binding Sites
Álvarez, L. D., Pecci, A., & Estrin, D. A. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01400 · Cited by 20
Bullock, A. E., Gunduz‐Bruce, H., Zammit, G. K., Qin, M., Li, H., Sankoh, A. J., Silber, C., Kanes, S., Jonas, J. M., & Doherty, J. (2021) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.2806 · Cited by 20
Self-citationBiologically active metabolites in drug discovery
Sun, S., & Wesolowski, S. S. (2021) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2021.128255 · Cited by 19
Gan, D., Li, C.-Z., Shu, Y., Jiapeng, W. A. N. G., Wang, C., Zhu, L., Yang, Y.-J., Jiaqi, L. I. U., He, B.-J., Cai, L., et al. (2023) · Chinese Journal of Natural Medicines · doi:10.1016/s1875-5364(23)60394-2 · Cited by 19
Clayton, A. H., Suthoff, E. D., Jain, R., Kosinski, M. R., Fridman, M., Deligiannidis, K. M., Meltzer-Brody, S. E., Chen, S., Gervitz, L. M., Huang, M., et al. (2024) · Journal of Affective Disorders · doi:10.1016/j.jad.2024.01.268 · Cited by 18
The emergence of antidepressant drugs targeting GABAA receptors: A concise review
Gonda, X., Tarazi, F. I., & Döme, P. (2024) · Biochemical Pharmacology · doi:10.1016/j.bcp.2024.116481 · Cited by 19
Jayakar, S. S., Chiara, D. C., Zhou, X., Wu, B., Bruzik, K. S., Miller, K. W., & Cohen, J. B. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.ra120.013452 · Cited by 18
Singh, K., Bhatia, R., Kumar, B., Singh, G., & Monga, V. (2021) · Current Neuropharmacology · doi:10.2174/1570159x19666211102154311 · Cited by 19
Synthetic neuroactive steroids as new sedatives and anaesthetics: Back to the future
Manzella, F. M., Covey, D. F., Jevtović‐Todorović, V., & Todorovic, S. M. (2021) · Journal of Neuroendocrinology · doi:10.1111/jne.13086 · Cited by 19
Zou, J., Yang, L., Yang, G., & Gao, J. (2023) · Psychiatry Research · doi:10.1016/j.psychres.2023.115450 · Cited by 18
Understanding the Clinical Effects and Mechanisms of Action of Neurosteroids
Kleinman, R. A., & Schatzberg, A. F. (2020) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2020.20020134 · Cited by 18
5β-Dihydrosteroids: Formation and Properties
Penning, T. M., & Covey, D. F. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25168857 · Cited by 16
“SAGE pharmaceuticals has developed an active NAS program and their clinically approved drug SAGE-217 (zuranolone 3 α -hydroxy-3 β -methyl-21-(4-cyano-1H-pyrazol-1-yl)-19-nor-5 β - pregnan-20-one) for the treatment of post-partum depression has a 5 β -configuration [52].”
BackgroundWang, P., Jensen, A. A., & Bunch, L. (2020) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.0c00600 · Cited by 16
Fasipe, O. J., Agede, O. A., & Enikuomehin, A. C. (2020) · Future Science OA · doi:10.2144/fsoa-2020-0108 · Cited by 18
Sivcev, S., Kudová, E., & Zemkova, H. W. (2023) · Neuropharmacology · doi:10.1016/j.neuropharm.2023.109542 · Cited by 16
Zawilska, J. B., & Zwierzyńska, E. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26136545 · Cited by 17
“On 4 August 2023, the FDA approved zuranolone (SAGE-217; ZURZUVAE™), developed by Sage Therapeutics Inc. (Cambridge, MA, USA) and Biogen Inc., (Cambridge, MA, USA) as the first oral neuroactive steroid-based drug for the treatment of PPD [45,76].”
Kudová, E., Mareš, P., Hill, M., Vondráková, K., Tsenov, G., Chodounská, H., Kubová, H., & Valeš, K. (2021) · Pharmaceuticals · doi:10.3390/ph15010049 · Cited by 15
Cutler, A. J., Mattingly, G. W., Kornstein, S. G., Aaronson, S. T., Lasser, R. A., Zhang, H., Rana, N., Brown, C., Levin, S. N., Miller, C., et al. (2023) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.23m14845 · Cited by 15
Self-citationBottemanne, H., Claret, A., & Fossati, P. (2020) · L Encéphale · doi:10.1016/j.encep.2020.08.006 · Cited by 15
Mechanisms and Pharmacotherapy for Ethanol-Responsive Movement Disorders
Wu, J., Tang, H., Chen, S., & Cao, L. H. (2020) · Frontiers in Neurology · doi:10.3389/fneur.2020.00892 · Cited by 12
Takasu, K., Yawata, Y., Tashima, R., Aritomi, H., Shimada, S., Onodera, T., Taishi, T., & Ogawa, K. (2024) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2023.1274459 · Cited by 11
Niu, C., Leavitt, L. S., Lin, Z., Paguigan, N. D., Sun, L., Zhang, J., Torres, J. P., Raghuraman, S., Chase, K., Cadeddu, R., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00562 · Cited by 11
Wu, B., Jayakar, S. S., Zhou, X., Titterton, K., Chiara, D. C., Szabo, A. L., Savechenkov, P. Y., Kent, D. E., Cohen, J. B., Forman, S. A., et al. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.11.019 · Cited by 10
Importance of achieving rapid treatment response in major depressive disorder
Alva, G. (2023) · CNS Spectrums · doi:10.1017/s1092852923002213 · Cited by 12
Berthonneau, C., Nun, P., Rivière, M., Pauvert, M., Dénès, F., & Lebreton, J. (2018) · The Journal of Organic Chemistry · doi:10.1021/acs.joc.7b03216 · Cited by 9
Future Pharmacotherapy for Bipolar Disorders: Emerging Trends and Personalized Approaches
Marano, G., Lisci, F. M., Boggio, G., Marzo, E. M., Abate, F., Sfratta, G., Traversi, G., Mazza, O., Pola, R., Sani, G., et al. (2025) · Future Pharmacology · doi:10.3390/futurepharmacol5030042 · Cited by 8
“Neuroactive steroids, such as allopregnanolone and its synthetic analogs, represent a novel and promising class of therapeutic agents due to their modulatory action on GABA-A receptors, particularly at δ -subunit-containing extrasynaptic sites [154,155].”
Zuranolone for treatment of major depressive disorder: a systematic review and meta-analysis
Ahmad, A., Awan, A. R., Nadeem, N., Javed, A. S., Farooqi, M., Daniyal, M., & Mumtaz, H. (2024) · Frontiers in Neuroscience · doi:10.3389/fnins.2024.1361692 · Cited by 9
Hormones and Steroids as Neurotransmitters
Marwein, S., Biswal, S., & Acharya, P. C. (2020) · Springer eBooks · doi:10.1007/978-981-15-3556-7_14 · Cited by 9
Pregnenolone sulfate analogues differentially modulate GABAA receptor closed/desensitised states
Mortensen, M., Xu, Y., Shehata, M. A., Krall, J., Ernst, M. C., Frølund, B., & Smart, T. G. (2023) · British Journal of Pharmacology · doi:10.1111/bph.16143 · Cited by 8
“…ring scaffold is broadly tolerated, affording analogues with variable potency at synaptic-and extrasynaptic-type GABA A Rs (Martinez et al., 2015; Martinez et al., 2017 We propose that this mechanism can become a new feature of GABA A R modulation, which may be exploited for future drug…”
BackgroundTrial of SAGE-217 in Patients with Major Depressive Disorder
Rosenblat, J. D. (2019) · New England Journal of Medicine · doi:10.1056/nejmc1913170 · Cited by 7
The importance of nitrile functionality: FDA-approved small molecules from 2021 to 2024
Tiz, D. B., Mangiavacchi, F., & Sancineto, L. (2026) · Phosphorus, sulfur, and silicon and the related elements · doi:10.1080/10426507.2025.2611024 · Cited by 6
Bhatti, N. A., Jobilal, A., Asif, K., Villegas, M. J., Pandey, P., Tahir, A. N., Balla, N. V. D. B., Camargo, M. P. A., Ahmad, S., Kataria, J., et al. (2023) · Cureus · doi:10.7759/cureus.44038 · Cited by 8
Extra-synaptic modulation of GABAA and efficacy in bipolar disorder
El‐Mallakh, R. S., & Ali, Z. (2021) · Medical Hypotheses · doi:10.1016/j.mehy.2021.110501 · Cited by 6
Ma, M., Xu, H., Liang, Y., Li, C., Zhu, H., Jiang, W., Wang, W., Yang, H., Yang, Y., Wang, Y., et al. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116602 · Cited by 6
Sequence and Structure-based Prediction of Allosteric Sites
Xie, J., Pan, G., & Lai, L. (2025) · Journal of Molecular Biology · doi:10.1016/j.jmb.2025.169305 · Cited by 5
Neurosteroids in the Pathophysiology and Treatment of Mood and Anxiety Disorders
Perkins, E. C., & Newport, D. J. (2018) · Current Treatment Options in Psychiatry · doi:10.1007/s40501-018-0159-8 · Cited by 6
Lecumberri, A. R., Gelabert, E., & García-Esteve, L. (2022) · Springer eBooks · doi:10.1007/978-3-030-91832-3_2 · Cited by 5
Xu, Y., Mortensen, M., Liebowitz, S., Jensen, N. N., Tian, Y., Bavo, F., Seidel, T., Smart, T. G., & Frølund, B. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c02881 · Cited by 4
Cha, D. S., Kleine, N., Teopiz, K. M., Vincenzo, J. D. D., Ho, R., Galibert, S. L., Samra, A., Zilm, S. P. M., Cha, R. H., d’Andrea, G., et al. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2023.2298340 · Cited by 4
Chvíla, S., Kubová, H., Mareš, P., Kudová, E., & Štĕpánek, F. (2024) · RSC Pharmaceutics · doi:10.1039/d3pm00043e · Cited by 4
Zhang, X., Ji, S., Yang, Y., Sun, X., Wang, H., Yang, Y., Deng, X., Wang, Y., Li, C., & Tian, J. (2024) · Molecules · doi:10.3390/molecules29225286 · Cited by 3
Clinical applications of small-molecule GABAAR modulators for neurological disorders
Chen, G., Xu, M., Chen, Z., & Yang, F. (2024) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2024.107983 · Cited by 4
The Application of the Pyrazole Structure in the Structural Modification of Natural Products
Sun, F.-Q., Wang, Y., Sun, K., Yue, F.-X., Sun, Y.-X., Ju, J.-H., Jin, Z.-H., Shen, Q., Guo, H., Liu, M.-H., et al. (2025) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/0113895575359419241211092252 · Cited by 3
New Therapeutic Modalities: Transforming Drug Discovery and Development
Blanco, M.-J. (2023) · Springer eBooks · doi:10.1007/978-3-030-73317-9_135-1 · Cited by 3
Self-citationThe mechanism of action and chemical synthesis of FDA newly approved drug molecules
Shen, D., Zhang, Y., Li, X., Bai, Y., Xiong, J., Seng, D., Zhang, Y., Liu, H., Yuan, S., & Yang, L. (2024) · Drug Development Research · doi:10.1002/ddr.22260 · Cited by 3
Metadata
- Authors
- Martinez Botella, G., Salituro, F. G., Harrison, B. L., Beresis, R. T., Bai, Z., Blanco, M.-J., Belfort, G. M., Dai, J., Loya, C. M., Ackley, M. A., Althaus, A. L., Grossman, S. J., Hoffmann, E., Doherty, J. J., & Robichaud, A. J.
- Affiliations
- Sage Therapeutics, Inc. 215 First Street, Cambridge, Massachusetts 02142, United States
- Sage Therapeutics (United States) (US)
- Shanghai Chempartner, 998 Halei Road, Shanghai 201203, China
- WuXi AppTec (China) (CN)
- Corresponding author
- Salituro, Francesco G.
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2017-08-17
- Volume
- 60
- Issue
- 18
- Pages
- 7810-7819
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W2740680044
- Cited by
- 129
- References
- 26
- Citations by year
- 2026: 11 · 2025: 11 · 2024: 24 · 2023: 21 · 2022: 9 · 2021: 16 · 2020: 16 · 2019: 12 · 2018: 8 · 2017: 1
- FWCI
- 4.95
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Medicinal Chemistry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Physical Sciences › Chemistry › Organic Chemistry › Heterocyclic Compound Synthesis and Bioactivity
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacological Receptor Mechanisms and Effects
- Keywords
- neurosteroids, GABAA receptor, positive allosteric modulators, structure-activity relationship, extrasynaptic GABAA receptors, oral bioavailability, pharmacokinetics, postpartum depression, major depressive disorder, essential tremor
- MeSH terms
- Allosteric Regulation, Animals, Depressive Disorder, Major, Major Depressive Disorder, Female, Pregnanolone, Pyrazoles, Receptors, GABA-A, Depression, Postpartum, Mice, Rats, GABA-A Receptor Agonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.